Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chugai Pharmaceutical Co Ltd (CHGCF)
OTHER OTC:CHGCF
Holding CHGCF?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.38Last Year’s EPS
0.36Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 24, 2018
|% Change Since: -2.58%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in operating profit and overseas sales, particularly driven by Hemlibra and Actemra exports. However, the company faced challenges with revenue decline due to the absence of Ronapreve and domestic market pressures. Despite these challenges, the strong performance in new product launches and improved cost structure suggest a positive outlook.Company Guidance
During the Chugai Pharmaceutical Q2 2024 earnings call, several key metrics and performance indicators were discussed. The company reported a 4.6% decline in revenue to JPY 552.9 billion, primarily due to the absence of Ronapreve supply; however, excluding Ronapreve, revenue increased by 10.9% or JPY 54.4 billion. Operating profit rose by 13.3% to JPY 262.8 billion, with an impressive operating margin of 47.5%. Hemlibra exports notably contributed to this profitability, with a 28.2% increase in overseas sales, adding JPY 59 billion. Despite the domestic sales decline due to NHI drug price revisions and generic drug penetration, Chugai anticipates achieving record high operating profit and net income for the full year. The strategic focus on R&D and drug discovery was emphasized, with plans to accelerate early-stage clinical development to enhance the success rate of new projects. The company also addressed the impact of the Inflation Reduction Act in the U.S., although it currently does not affect their products. Overall, Chugai is on track with its long-term strategy, TOP I 2030, and is optimistic about future growth prospects.Operating Profit Increase
Operating profit increased by 13.3% to JPY 262.8 billion, despite a revenue decline.
Hemlibra Export Growth
Hemlibra export grew significantly, contributing to the overall performance, with international sales up by 32%.
Strong Overseas Sales
Overseas sales increased by JPY 59 billion or 28.2%, driven by Hemlibra and Actemra.
Improved Cost of Sales Ratio
Cost of sales ratio improved significantly to 30.3% due to product mix changes.
New Product Launches
Successful launch of several new products, including PiaSky and Mitchga, with strong market reception.
R&D Progress
Significant R&D output increase, with several projects moving into clinical development stages.
---
CHGCF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CHGCF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 25, 2024 | $43.37 | $43.18 | -0.44% |
| Jul 25, 2024 | $39.58 | $39.21 | -0.93% |
| Apr 24, 2024 | $33.52 | $32.43 | -3.25% |
| Feb 01, 2024 | $36.44 | $36.29 | -0.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Chugai Pharmaceutical Co Ltd (CHGCF) report earnings?
Chugai Pharmaceutical Co Ltd (CHGCF) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Chugai Pharmaceutical Co Ltd (CHGCF) earnings time?
Chugai Pharmaceutical Co Ltd (CHGCF) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CHGCF EPS forecast?
CHGCF EPS forecast for the fiscal quarter 2024 (Q4) is 0.38.
---